Succinate dehydrogenase expression in breast cancer

Sewha Kim, Do Hee Kim, Woo-Hee Jung and Ja Seung Koo*

Abstract

The aim of this study was to investigate succinate dehydrogenase (SDH) expression in breast cancer according to breast cancer molecular subtype using immunohistochemistry and to assess the clinical implications of SDH expression. Immunohistochemical staining for ER, PR, HER-2, Ki-67, HIF-1α, SDHA, and SDHB was performed on tissue microarrays of 721 breast cancers. According to the immunohistochemistry results for ER, PR, HER-2, and Ki-67 and fluorescence in situ hybridization (FISH) results for HER-2, breast cancer molecular subtypes were classified into luminal A, luminal B, HER-2, and triple-negative breast cancer (TNBC). HER-2 subtype breast cancers most frequently showed high-level expression of SDHA in tumor cells, while the luminal A subtype most frequently showed low or negative expression of SDHA in tumor cells ($P$ = 0.032). Stromal SDHB expression rate was highest in HER-2 subtype and lowest in TNBC ($P$ < 0.001). SDHA-negative breast cancers were associated with younger age at diagnosis ($P$ = 0.012), and SDHB-negative breast cancers with lower histologic grade ($P$ = 0.044) and lower Ki-67 labeling index (LI) ($P$ = 0.046). Tumor phenotypes according to the SDH status were SDHA(+) /SDHB(+) > SDHA(−)/SDHB(+) > SDHA(−)/SDHB(−) in order of frequency. The stromal phenotypes were SDHA(−)/SDHB(−) > SDHA(+) /SDHB(+) > SDHA(−)/SDHB(+) > SDHA(+) /SDHB(−). In conclusion, loss of SDHA or SDHB expression was observed in about 3% of breast cancers in this study. Low SDH expression status in breast tumor cells was associated with younger age at diagnosis and low-grade histology.

Keywords: Breast; Metabolism; Mitochondria; Succinate dehydrogenase

Introduction

Succinate dehydrogenase (SDH) (succinate-coenzyme Q reductase, respiratory Complex II) catalyzes the oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol. Through the coupling of these two reactions in the inner mitochondrial membrane, SDH links glucose oxidation in the TCA cycle with ATP production in the mitochondria (Cardaci & Ciriolo 2012; King et al. 2006; Barletta & Hornick 2012; Van Nederveen et al. 2009). SDH is composed of four subunits; SDHA, SDHB, SDHC and SDHD. The first two are hydrophilic proteins protruding into the mitochondrial matrix, and the second two are hydrophobic proteins that anchor the catalytic core into the inner mitochondrial membrane (Cardaci & Ciriolo 2012; King et al. 2006; Barletta & Hornick 2012; Van Nederveen et al. 2009).

Germline loss-of-function SDH mutations are associated with several tumors such as pheochromocytoma and paraganglioma, gastrointestinal stromal tumor (GIST), and renal cell carcinoma (Hensen & Bayley 2011; Kantorovich et al. 2010; Anderson et al. 2004; Astuti et al. 2001; Miettinen et al. 2011; Badve et al. 2011; Ricketts et al. 2008). Among these, GIST and renal cell carcinoma are reported to display histologic features that distinguish SDH-deficient tumors (Miettinen et al. 2011). Although SDH germline mutation may be accurately evaluated by gene sequencing, a few recent studies have shown very high sensitivity for immunohistochemical detection of SDH mutation in GIST, pheochromocytoma, and paraganglioma (Van Nederveen et al. 2009; Gill et al. 2010a; Miettinen et al. 2013; Janeway et al. 2011).

To date, few studies have investigated SDH expression in breast cancer. We investigated SDH expression status according to breast cancer molecular subtype using immunohistochemical methods and assessed the clinical implications of SDH expression in breast cancer.

* Correspondence: kjs1976@yuhhs.ac
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea

© 2013 Kim et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Materials and methods

Patient selection
Patients who were diagnosed with invasive ductal carcinoma, not otherwise specified and underwent surgical excision at Severance Hospital between January 2002 and December 2005 were included in the study. Patients who received preoperative hormonal therapy or neoadjuvant chemotherapy were excluded. All hematoxylin and eosin (H&E)-stained slides for each case were retrospectively reviewed by breast pathologists (Koo JS). The histological grade was assessed using the Nottingham grading system. (Elston & Ellis 1991) The clinicopathologic parameters evaluated for each breast cancer included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, distant metastasis, and patient survival. The Institutional Review Board of Yonsei University Severance Hospital approved this study.

Tissue microarray
On H&E-stained slides of tumors, a representative area was selected and a corresponding spot was marked on the surface of the paraffin block. Using a biopsy needle, the selected area was punched out and a 3-mm core of tumor tissue was placed onto a 6 × 5 recipient block. Two tissue cores were extracted from each sample to minimize bias. Each tissue core was assigned a unique tissue microarray location number that was linked to clinicopathologic data in a database.

Immunohistochemistry
All immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue sections using antibodies as indicated (Table 1). Briefly, 5-μm-thick sections were obtained with a microtome, transferred onto adhesive slides, and dried at 62 °C for 30 min. After incubation with primary antibodies, immunodetection was performed with biotinylated antimouse immunoglobulin, followed by peroxidase-labeled streptavidin using a labeled streptavidin kit with 3,3′-diaminobenzidine chromagen as substrate. The primary antibody incubation step was omitted in the negative control. Slides were counterstained with Harris hematoxylin.

Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed by light microscopy. Parameters such as ER, PR, and HER-2 status were obtained from patients’ pathologic reports. A cut-off value of 1% or more positively stained nuclei was used to define ER and PR positivity (Hammond et al. 2010). HER-2 staining was analyzed according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines using the following categories: 0, no immunostaining; 1+, weak incomplete membranous staining, less than 10% of tumor cells; 2+, complete membranous staining, either uniform or weak in at least 10% of tumor cells; and 3+, uniform intense membranous staining in at least 30% of tumor cells (Wolff AC, et al. 2007). HER-2 immunostaining was recorded as positive when strong (3+) membranous staining was observed, whereas staining categories 0 to 1+ were recorded as negative. Samples showing 2+ HER-2 expression were evaluated for HER-2 amplification by fluorescence in situ hybridization (FISH).

Immunohistochemical staining for SDHA and SDHB showed cytoplasmic expression with a granular pattern. Complete loss of expression was considered negative, while cytoplasmic expression in less than 50% of tumor cells was considered low expression, and cytoplasmic expression in more than 50% of tumor cells was considered high expression (Figure 1). HIF-1α was considered positive when more than 10% of tumor cells showed strong cytoplasmic or nuclear expression.

Fish analysis
FISH was performed using a PathVysion HER-2 DNA Probe Kit (Vysis, Downers Grove, IL, USA) according to the manufacturer’s instructions. Invasive tumors were first examined on hematoxylin-eosin-stained slides to confirm histology. HER-2 gene copy number on the slides was evaluated using an epifluorescence microscope (Olympus, Tokyo, Japan) according to the ASCO/CAP guidelines (Wolff AC, et al. 2007). At least 60 tumor cell nuclei in three separate regions were investigated for HER-2 and chromosome 17 signals. An absolute HER-2 gene copy number lower than 4 or an HER-2 gene/chromosome 17 copy number ratio (HER-2/Chr17 ratio) less than 1.8 was considered HER-2-negative. An absolute HER-2 copy number between 4 and 6 or an HER-2/Chr17 ratio between 1.8 and 2.2 was considered HER-2-equivocal. An absolute HER-2 copy number greater than 6 or an HER-2/Chr17 ratio higher than 2.2 was considered HER-2-positive.

Table 1 Clone, dilution, and source of antibodies used

| Antibody | Clone | Dilution | Company                        |
|----------|-------|----------|--------------------------------|
| HIF-1α   | EP1215Y | 1:100    | Biocare, Yorba Linda, CA, USA  |
| SDHA     | 2E3GC12FB2AE2 | 1:100 | Abcam, Cambridge, UK          |
| SDHB     | 21A11AE7  | 1:100    | Abcam, Cambridge, UK          |
| Tumor phenotype-related | | | |
| ER       | SPI    | 1:100    | Thermo Scientific, CA, USA    |
| PR       | PgR    | 1:50     | DAKO, Denmark                  |
| HER-2    | Polyclonal | 1:1500  | DAKO, Denmark                  |
| Ki-67    | MIB-1  | 1:150    | DAKO, Glostrup, Denmark        |

ER estrogen receptor; PR progesterone receptor, EGFR epidermal growth factor receptor.
Tumor phenotype classification
Breast cancer phenotypes were classified according to the immunohistochemistry results for ER, PR, HER-2, and Ki-67 and the FISH results for HER-2 as follows (Goldhirsch A, et al. 2011): Luminal A subtype as ER- or/and PR-positive and HER-2-negative and Ki-67 LI <14%; Luminal B subtype as ER- or/and PR-positive and HER-2-negative and Ki-67 LI ≥14%; HER-2 positive as ER- or/and PR-positive and HER-2 overexpressed or/and amplified; HER-2-overexpression subtype as ER- and PR-negative and HER-2 overexpressed or/and amplified; and triple-negative breast cancer (TNBC) subtype as ER-, PR-, and HER-2-negative.

Statistical analysis
Data were analyzed using SPSS for Windows, Version 12.0 (SPSS Inc., Chicago, IL, USA). Student’s t and Fisher’s exact tests were used to evaluate continuous and categorical variables, respectively. The significance level was set at 0.05. The time to tumor recurrence and overall survival were evaluated by Kaplan-Meier and log-rank statistics. Multivariate regression analysis was performed using the Cox proportional hazards model.

Results
Patients’ characteristics
Clinicopathological characteristics according to breast cancer molecular subtype are shown in Table 2. Molecular subtypes among these 721 breast cancers included 302 luminal A (41.9%), 168 luminal B (23.3%), 69 HER-2 type (9.6%), and 182 TNBC (25.2%). TNBC showed higher histologic grade (P < 0.001), higher T stage (P = 0.007), and higher Ki-67 LI (P < 0.001) than other molecular subtypes. The HER-2 subtype was positively associated with age (P = 0.005) and with tumor recurrence and death (P = 0.001).

HIF-1α and sdh status according to molecular subtype of breast cancer
HIF-1α, SDHA, and SDHB expression according to breast cancer subtype are shown in Table 3 and Figure 2. Only 24 (3.3%) and 4 (0.6%) of 721 breast cancers displayed HIF-1α expression in the nucleus and cytoplasm, respectively. The HER-2 tumor subtype showed the highest frequency of high SDHA expression, and the luminal A subtype most frequently showed low or negative SDHA expression (P = 0.032). Stromal SDHB expression frequency was highest in the HER2 subtype and lowest in TNBC (P < 0.001). Stromal SDHA expression was detected most frequently in the HER-2 subtype, although the correlation was not significant (P = 0.063). Nuclear HIF-1α expression and SDHA/SDHB expression did not correlate significantly (Table 4); however, SDHA and SDHB expression were correlated significantly (r = 0.895, P < 0.001, Figure 3).

Clinicopathologic characteristics of breast cancer with SDHA and/or SDHB negativity
Clinicopathologic characteristics of breast cancers were compared between the SDHA/SDHB positive and negative breast cancers (Table 5). Tumor negativity for SDHA correlated with earlier age at diagnosis of breast cancer (P = 0.012) and with lower histologic grade (P = 0.062). SDHB-negative breast cancer correlated with lower histologic grade (P = 0.044) and lower Ki-67 LI (P = 0.046). There was no correlation between the expression status of SDH and that of nuclear HIF-1α (Table 4).

Correlations between clinicopathologic parameters and expression of HIF-1α and SDH
Correlation analysis between HIF-1α and SDH expression and clinicopathologic factors revealed an association of nuclear HIF-1α expression with PR negativity (P = 0.011), and of low or negative SDHA expression in the tumor with ER positivity (P = 0.044), HER-2 negativity (P = 0.021), and higher T stage (P = 0.031). Low or negative SDHB expression in the tumor was associated with higher T stage (P = 0.011). Stromal SDHB negativity was associated with HER-2 negativity (P < 0.001, Table 6).

Clinicopathologic features according the phenotype of SDH expression in breast cancer
The SDHA/SDHB expression phenotypes in these 712 breast tumors were, in order of frequency, SDHA(+)SDHB(+) > SDHA(−)/SDHB(−) > SDHA(−)/SDHB(+) > SDHA(+)SDHB(−). The stroma phenotypes were SDHA

Figure 1 Immunohistochemical evaluation of SDHB expression. (A) negative (B) low positive (C) high positive.
Table 2 Clinicopathologic characteristics according to breast cancer phenotype

| Parameters                              | Total n = 721 (%) | Luminal A n = 302 (%) | Luminal B n = 168 (%) | HER-2 n = 69 (%) | TNBC n = 182 (%) | P-value |
|-----------------------------------------|------------------|-----------------------|-----------------------|-----------------|-----------------|---------|
| Age (years, mean ± SD)                  | 49.6 ± 10.9      | 50.6 ± 10.4           | 48.4 ± 10.0           | 52.4 ± 10.0     | 48.0 ± 12.4     | 0.005   |
| Histologic grade (I – III)              |                  |                       |                       |                 |                 |         |
| I                                       | 120 (16.6)       | 92 (30.5)             | 20 (11.9)             | 1 (1.4)         | 7 (3.8)         | <0.001  |
| II                                      | 364 (50.5)       | 182 (60.3)            | 91 (54.2)             | 36 (52.2)       | 55 (30.2)       |         |
| III                                     | 237 (32.9)       | 28 (9.3)              | 57 (33.9)             | 32 (46.4)       | 120 (65.9)      |         |
| Tumor stage (T1 – T3)                   |                  |                       |                       |                 |                 | 0.007   |
| T1                                      | 350 (48.5)       | 167 (55.3)            | 85 (50.6)             | 30 (43.5)       | 68 (37.4)       |         |
| T2                                      | 356 (49.4)       | 127 (42.1)            | 81 (48.2)             | 38 (55.1)       | 110 (60.4)      |         |
| T3                                      | 15 (2.1)         | 8 (2.6)               | 2 (1.2)               | 1 (1.4)         | 4 (2.2)         |         |
| Nodal stage (N0 – N3)                   |                  |                       |                       |                 |                 | 0.060   |
| N0                                      | 425 (58.9)       | 171 (56.6)            | 92 (54.8)             | 42 (60.9)       | 120 (65.9)      |         |
| N1                                      | 192 (26.6)       | 89 (29.5)             | 43 (25.6)             | 13 (18.8)       | 47 (25.8)       |         |
| N2                                      | 65 (9.0)         | 27 (8.9)              | 18 (10.7)             | 9 (13.0)        | 11 (6.0)        |         |
| N3                                      | 39 (5.4)         | 15 (5.0)              | 15 (8.9)              | 5 (7.2)         | 4 (2.2)         |         |
| Estrogen receptor status (Negative – Positive) | 261 (36.2) | 5 (1.7)               | 5 (3.0)               | 69 (100.0)      | 182 (100.0)     | <0.001  |
| Progesterone receptor status (Negative – Positive) | 460 (63.8) | 297 (98.3)            | 163 (97.0)            | 0 (0.0)         | 0 (0.0)         |         |
| HER-2 status (Negative – Positive)      | 346 (48.0)       | 49 (16.2)             | 46 (27.4)             | 69 (100.0)      | 182 (100.0)     | <0.001  |
| Ki-67 LI (% mean ± SD)                  | 573 (79.5)       | 302 (100.0)           | 89 (53.0)             | 0 (0.0)         | 182 (100.0)     | <0.001  |
| Tumor recurrence (Negative – Positive)   | 148 (20.5)       | 0 (0.0)               | 79 (47.0)             | 69 (100.0)      | 0 (0.0)         |         |
| Tumor recurrence (%, mean ± SD)         | 17.3 ± 18.4      | 4.7 ± 3.7             | 19.6 ± 12.6           | 19.3 ± 12.8     | 35.1 ± 23.0     | <0.001  |
| Patient death (Negative – Positive)     | 63 (8.7)         | 14 (46.2)             | 13 (7.7)              | 11 (15.9)       | 25 (13.7)       | 0.001   |
| Duration of clinical follow-up (months) (mean ± SD) | 70.0 ± 31.2 | 72.4 ± 29.3           | 70.2 ± 30.0           | 65.2 ± 34.3     | 67.8 ± 34.2     | 0.234   |

TNBC triple negative breast cancer.

(-)/SDHB(-) > SDHA(+)/SDHB(+) > SDHA(-)/SDHB(+) > SDHA(+)/SDHB(-) (Table 7).

SDHA(+)/SDHB(+) tumors tended to have higher histologic grades than SDHA(+)/SDHB(-) and SDHA(-)/SDHB(-) tumors (P = 0.038). Stromal SDHA(-)/SDHB(+) tumors showed the highest frequency of HER-2 positivity, while stromal SDHA(+)/SDHB(-) tumors showed lowest HER-2 positivity (P = 0.001). Stromal SDHA/SDHB phenotype differed significantly between the molecular subtypes, SDHA (+)/SDHB(+) being most frequent in Luminal A and least in TNBC tumors. The SDHA(+)/SDHB(-) phenotype was most frequent in TNBC and least frequent in HER-2 subtype tumors; SDHA(-)/SDHB(+) was most frequent in Luminal B and least in TNBC; and SDHA(-)/SDHB(-) was most frequent in the Luminal A and least in the HER-2 subtype (P < 0.001).

Prognostic significance of HIF-1α and SDH expression status

In univariate analysis, neither HIF-1α nor SDH expression was significantly related to patient outcome (Table 8). In multivariate Cox analysis (Table 9), factors negatively associated with DFS were T stage (Hazard ratio: 2.535, 95% CI: 1.376 – 4.670, P = 0.003), lymph node metastasis (Hazard ratio: 2.257, 95% CI: 1.335 – 3.816, P = 0.002), and high histologic grade (Hazard ratio: 1.685, 95% CI: 1.013 – 2.804, P = 0.003). Factors negatively associated with OS were T stage (Hazard ratio: 2.218, 95% CI: 1.229 – 4.001, P = 0.008), lymph node metastasis (Hazard ratio: 1.831, 95% CI: 1.076 – 3.115, P = 0.026), high tumor expression of SDHA (Hazard ratio: 4.157, 95% CI: 1.657 – 10.432, P = 0.002), and low SDHB expression (Hazard ratio: 3.223, 95% CI: 1.295 – 8.025, P = 0.012).
Germline defects in SDH, particularly in SDHA and SDHB, have been detected in several tumor types, including pheochromocytomas (Van Nederveen et al. 2009; Astuti et al. 2001), paragangliomas (Van Nederveen et al. 2009; Astuti et al. 2001; Baysal 2003; Burnichon et al. 2010), GISTs (Gaal et al. 2011; Gill et al. 2010b; Gill et al. 2011a), and renal cell carcinomas (Gill et al. 2011b). Until recently, the accurate detection of SDH mutation depended primarily on direct sequencing and western blotting, methods that a clinical laboratory may find too costly and time-consuming. However, in a study of paraganglioma and pheochromocytoma, Van Nederveen et al. demonstrated the high sensitivity of immunohistochemical

The expression of HIF-1α and SDH according to tumor phenotype is shown in Table 3. The table indicates the expression levels of HIF-1α and SDH in different tumor subtypes, including Luminal A, Luminal B, HER-2, and TNBC. The expression levels are categorized as Negative, Low, or Positive, and the P-values are reported for each category. The table highlights the variability in expression levels across different tumor subtypes and the statistical significance of these differences.

### Table 3 Expression of HIF-1α and SDH according to tumor phenotype

| Parameters               | Luminal A n = 302 (%) | Luminal B n = 168 (%) | HER-2 n = 69 (%) | TNBC n = 182 (%) | P-value |
|--------------------------|-----------------------|-----------------------|-----------------|-----------------|---------|
| Nuclear HIF-1α           |                       |                       |                 |                 | 0.319   |
| Negative                 | 697 (96.7)            | 296 (98.0)            | 161 (95.8)      | 65 (94.2)       |         |
| Positive                 | 24 (3.3)              | 6 (2.0)               | 7 (4.2)         | 4 (5.8)         |         |
| Cytoplasmic HIF-1α       |                       |                       |                 |                 | 0.596   |
| Negative                 | 717 (99.4)            | 301 (99.7)            | 166 (98.8)      | 69 (100.0)      |         |
| Positive                 | 4 (0.6)               | 1 (0.3)               | 2 (1.2)         | 0 (0.0)         |         |
| Tumoral SDHA             |                       |                       |                 |                 | 0.032   |
| Negative/Low             | 41/319 (49.9)         | 21/143 (54.3)         | 8/76 (50.0)     | 5/19 (34.8)     | 0.032   |
| High                     | 361 (50.1)            | 138 (45.7)            | 84 (50.0)       | 45 (65.2)       |         |
| Stromal SDHA             |                       |                       |                 |                 | 0.063   |
| Negative                 | 665 (92.2)            | 286 (94.7)            | 153 (91.1)      | 59 (85.5)       |         |
| Positive                 | 56 (7.8)              | 16 (5.3)              | 15 (8.9)        | 10 (14.5)       |         |
| Tumoral SDHB             |                       |                       |                 |                 | 0.291   |
| Negative/Low             | 24/245 (37.3)         | 15/103 (39.1)         | 3/56 (51.1)     | 3/19 (31.9)     |         |
| High                     | 452 (62.7)            | 184 (60.9)            | 109 (49.0)      | 47 (68.1)       |         |
| Stromal SDHB             |                       |                       |                 |                 | <0.001  |
| Negative                 | 641 (88.9)            | 277 (91.7)            | 142 (84.5)      | 51 (73.9)       |         |
| Positive                 | 80 (11.1)             | 25 (8.3)              | 26 (15.5)       | 18 (26.1)       |         |

TNBC: triple negative breast cancer.

**Discussion**

Germline defects in SDH, particularly in SDHA and SDHB, have been detected in several tumor types, including pheochromocytomas (Van Nederveen et al. 2009; Astuti et al. 2001), paragangliomas (Van Nederveen et al. 2009; Astuti et al. 2001; Baysal 2003; Burnichon et al. 2010), GISTs (Gaal et al. 2011; Gill et al. 2010b; Gill et al. 2011a), and renal cell carcinomas (Gill et al. 2011b). Until recently, the accurate detection of SDH mutation depended primarily on direct sequencing and western blotting, methods that a clinical laboratory may find too costly and time-consuming. However, in a study of paraganglioma and pheochromocytoma, Van Nederveen et al. demonstrated the high sensitivity of immunohistochemical

Figure 2: Expression of SDHA and SDHB according to the molecular subtype of breast cancer. Tumor cells showed highest SDHA expression in the HER-2 subtype and lowest SDHA expression in the luminal A subtype. Stromal elements expressed SDHA at lower levels than tumor cells.
methods to detect germline mutations in SDH (Van Nederveen et al. 2009). While the tumors with SDHB, SDHC, or SDHD germline mutations exhibited a loss of SDHB immunorepression with intact SDHA expression, tumors with SDHA germline mutations exhibited a loss of expression of both SDHA and SDHB. Using similar methods in the present study, we found that 23 of 721 breast cancer patients (3.19%) had SDHA mutation (SDHA+/SDHB– expression) and one patient (0.1%) had an SDHB mutation (SHDA+/SDHB– expression; Table 7). As few previous studies have evaluated SDH mutation in breast cancer, these findings provide a starting point for future investigations. However, a

| Factors       | Nuclear HIF-1α | Cytoplasmic HIF-1α |
|---------------|----------------|--------------------|
|               | Negative n = 697 (%) | Positive n = 24 (%) | P-value | Negative n = 717 (%) | Positive n = 4 (%) | P-value |
| Tumoral SDHA  |                |                    |         |                |                    |         |
| Negative      | 40 (5.7)       | 1 (4.2)            | 0.247   | 40 (5.6)       | 1 (25.0)           | 0.518   |
| Low           | 311 (44.6)     | 8 (33.3)           |         | 318 (44.4)     | 1 (25.0)           |         |
| High          | 346 (49.6)     | 15 (62.5)          |         | 359 (50.1)     | 0 (0.0)            |         |
| Stromal SDHA  |                |                    | 0.423   |                |                    | 1.000   |
| Negative      | 644 (92.4)     | 21 (87.5)          |         | 661 (92.2)     | 4 (100.0)          |         |
| Positive      | 53 (7.6)       | 3 (12.5)           |         | 56 (7.8)       | 0 (0.0)            |         |
| Tumoral SDHB  |                |                    | 0.926   |                |                    | 0.032   |
| Negative      | 24 (3.4)       | 0 (0.0)            |         | 23 (3.2)       | 1 (25.0)           |         |
| Low           | 235 (33.7)     | 10 (41.7)          |         | 243 (33.9)     | 2 (50.0)           |         |
| High          | 438 (62.8)     | 14 (58.3)          |         | 451 (62.8)     | 1 (25.0)           |         |
| Stromal SDHB  |                |                    | 0.328   |                |                    | 1.000   |
| Negative      | 621 (89.1)     | 20 (83.3)          |         | 637 (88.8)     | 4 (100.0)          |         |
| Positive      | 76 (10.9)      | 4 (16.7)           |         | 80 (11.2)      | 0 (0.0)            |         |

SDH succinate dehydrogenase.

Figure 3 Correlation between SDHA and SDHB expression.
previous study reported that SDH germline mutations or variants occur in some patients with Cowden syndrome (CS) who do not present the expected PTEN mutation. Compared with patients positive for germline PTEN mutation, these CS/CS-like individuals develop cancers of the breast, thyroid, and kidney at higher frequencies (Ni et al. 2008). Therefore, some breast cancer patients may be expected to have SDH mutations.

Findings in this study may be limited in that the sensitivity of immunohistochemistry in detecting SDH mutation as compared to direct sequencing has not been tested in breast cancer. We have assumed a degree of reliability in breast cancer similar to that of the detection of SDH germline mutations in paraganglioma and pheochromocytoma (Van Nederveen et al. 2009). To confirm SDH mutation, loss of SDH expression should be tested throughout the entire tumor (Barletta & Hornick 2012), whereas in this study, immunohistochemistry was performed on the tissue microarray only.

In previous studies of pheochromocytoma and GIST, SDH-deficient tumors showed complete loss of cytoplasmic granular expression (Miettinen et al. 2011; Gimenez-Roqueplo et al. 2003). Even though weak, focal or diffuse cytoplasmic staining was observed in a very few tumor cells of SDH-deficient tumor, this finding may be considered negative, because it is clearly distinguishable from the strong speckled expression pattern in surrounding non-neoplastic elements. However, stromal cells did not express SDHA and SDHB in most breast cancers in this study, which made it impossible to compare the staining intensity between tumor cells and internal normal controls (stromal cells). Therefore, expression in tumor cells was interpreted at three grade levels according to the proportion of cells stained: grade (1),

Table 5 Clinicopathologic characteristics of breast cancer with SDHA and/or SDHB negativity in tumor cells

| Parameters                  | SDHA (n = 41) | SDHB (n = 680) | P-value | SDHA (n = 24) | SDHB (n = 697) | P-value |
|-----------------------------|---------------|----------------|---------|---------------|----------------|---------|
| Age (years, mean ± SD)      |               |                |         |               |                |         |
| 45.4 ± 10.3                 | 49.9 ± 10.9   | 0.012          | 46.9 ± 9.1 | 49.7 ± 10.9  | 0.212          |
| Histologic grade            |               |                |         |               |                |         |
| I/II                        | 33 (80.5)     | 451 (66.3)     | 0.062  | 21 (87.5)     | 463 (66.4)     | 0.044   |
| III                         | 8 (19.5)      | 229 (33.7)     | 0.405  | 3 (12.5)      | 234 (33.6)     | 0.286   |
| ER                          |               |                |         |               |                |         |
| Negative                    | 12 (29.3)     | 249 (36.6)     | 0.405  | 6 (25.0)      | 255 (36.6)     | 0.286   |
| Positive                    | 29 (70.7)     | 431 (63.4)     | 0.748  | 18 (75.0)     | 442 (63.4)     | 1.000   |
| PR                          |               |                |         |               |                |         |
| Negative                    | 21 (51.2)     | 325 (47.8)     | 0.750  | 11 (45.8)     | 335 (48.1)     | 0.213   |
| Positive                    | 20 (48.8)     | 355 (52.2)     | 0.693  | 13 (54.2)     | 362 (51.9)     | 0.800   |
| HER-2                       |               |                |         |               |                |         |
| Negative                    | 34 (82.9)     | 539 (79.3)     | 0.625  | 20 (83.3)     | 553 (79.3)     | 0.529   |
| Positive                    | 7 (17.1)      | 141 (20.7)     | 0.750  | 4 (16.7)      | 144 (20.7)     | 0.213   |
| Tumor stage                 |               |                |         |               |                |         |
| T1                          | 21 (51.2)     | 329 (48.4)     | 0.693  | 15 (62.5)     | 335 (48.1)     | 0.800   |
| T2/T3                       | 20 (48.8)     | 351 (51.6)     | 0.750  | 9 (37.5)      | 362 (51.9)     | 1.000   |
| Nodal stage                 |               |                |         |               |                |         |
| N0                          | 26 (63.4)     | 399 (58.7)     | 0.625  | 16 (66.7)     | 409 (58.7)     | 0.529   |
| N1/N2/N3                    | 15 (36.6)     | 281 (41.3)     | 0.750  | 8 (33.3)      | 288 (41.3)     | 0.213   |
| Molecular subtypes          |               |                |         |               |                |         |
| Luminal A                   | 21 (51.2)     | 281 (41.3)     | 0.452  | 15 (62.5)     | 287 (41.2)     | 0.134   |
| Luminal B                   | 8 (19.5)      | 160 (23.5)     | 0.750  | 3 (12.5)      | 165 (23.7)     | 0.213   |
| HER-2                       | 5 (12.2)      | 64 (9.4)       | 0.452  | 3 (12.5)      | 66 (9.5)       | 0.134   |
| TNBC                        | 7 (17.1)      | 175 (25.7)     | 0.750  | 3 (12.5)      | 179 (25.7)     | 0.213   |
| Ki-67 LI (% mean ± SD)      | 13.0 ± 12.3   | 17.5 ± 18.7    | 0.012  | 9.9 ± 10.0    | 17.5 ± 18.6    | 0.046   |
| Tumor recurrence            | 4 (9.8)       | 59 (8.7)       | 0.750  | 1 (4.2)       | 62 (8.9)       | 0.714   |
| Patient death               | 4 (9.8)       | 56 (8.2)       | 0.750  | 1 (4.2)       | 59 (8.5)       | 0.713   |

SDH succinate dehydrogenase, TNBC triple negative breast cancer.
| Parameters | Nuclear HIF-1α | Cytoplasmic HIF-1α | Tumor SDHA | Tumor SDHA | Stroma SDHA | Stroma SDHA |
|------------|----------------|------------------|------------|------------|------------|------------|
|            | - | + | P | - | + | P | - | + | P | - | + | P | - | + | P |
| Histologic grade | 0.270 | 0.601 | 0.342 | 0.105 | 0.870 | 0.528 |
| I/II | 465 (66.7) | 19 (79.2) | 482 (67.2) | 2 (50.0) | 248 (68.9) | 236 (65.4) | 452 (68.0) | 32 (57.1) | 182 (67.7) | 302 (66.8) | 433 (67.6) | 51 (63.8) |
| III | 232 (33.3) | 5 (20.8) | 235 (32.8) | 2 (50.0) | 112 (31.2) | 125 (34.6) | 213 (32.0) | 24 (42.9) | 87 (32.3) | 150 (33.2) | 208 (32.4) | 29 (36.3) |
| ER | 0.388 | 1.000 | 0.044 | 0.111 | 0.873 | 0.806 |
| Negative | 250 (35.9) | 11 (45.8) | 260 (36.3) | 1 (25.0) | 117 (32.5) | 144 (39.9) | 235 (35.3) | 26 (46.4) | 96 (35.7) | 165 (36.5) | 231 (36.0) | 30 (37.5) |
| Positive | 447 (64.1) | 13 (54.2) | 457 (63.7) | 3 (75.0) | 243 (67.5) | 217 (60.1) | 430 (64.7) | 30 (53.6) | 173 (64.3) | 287 (63.5) | 410 (64.0) | 50 (62.5) |
| PR | 0.011 | 1.000 | 0.118 | 0.165 | 0.645 | 1.000 |
| Negative | 328 (47.1) | 18 (75.0) | 344 (48.0) | 2 (50.0) | 162 (45.0) | 184 (51.0) | 314 (47.2) | 32 (57.1) | 126 (46.8) | 220 (48.7) | 308 (48.0) | 38 (47.5) |
| Positive | 369 (52.9) | 6 (25.0) | 373 (52.0) | 2 (50.0) | 198 (55.0) | 177 (49.0) | 351 (52.8) | 24 (42.9) | 143 (53.2) | 232 (51.3) | 333 (52.0) | 42 (52.5) |
| HER-2 | 0.304 | 1.000 | 0.021 | 0.083 | 0.057 | <0.001 |
| Negative | 556 (79.8) | 17 (70.8) | 570 (79.5) | 3 (75.0) | 299 (83.1) | 274 (75.9) | 534 (80.3) | 39 (69.6) | 224 (83.3) | 349 (77.2) | 526 (82.1) | 47 (58.8) |
| Positive | 141 (20.2) | 7 (29.2) | 147 (20.5) | 1 (25.0) | 61 (16.9) | 87 (24.1) | 131 (19.7) | 17 (30.4) | 45 (16.7) | 103 (22.8) | 115 (17.9) | 33 (41.3) |
| Tumor stage | 0.304 | 1.000 | 0.031 | 1.000 | 0.011 | 0.237 |
| T1 | 341 (48.9) | 9 (37.5) | 348 (48.5) | 2 (50.0) | 160 (44.4) | 190 (52.6) | 323 (48.6) | 27 (48.2) | 114 (42.4) | 236 (52.2) | 306 (47.7) | 44 (55.0) |
| T2/T3 | 356 (51.1) | 15 (62.5) | 369 (51.5) | 2 (50.0) | 200 (55.6) | 171 (47.4) | 342 (51.4) | 29 (51.8) | 155 (57.6) | 216 (47.8) | 335 (52.3) | 36 (45.0) |
| Nodal stage | 0.208 | 0.648 | 0.198 | 0.575 | 0.639 | 0.149 |
| N0 | 414 (59.4) | 11 (45.8) | 422 (58.9) | 3 (75.0) | 221 (61.4) | 204 (56.5) | 394 (59.2) | 31 (55.4) | 162 (60.2) | 263 (58.2) | 384 (59.9) | 41 (51.3) |
| N1/N2/N3 | 283 (40.6) | 13 (54.2) | 295 (41.1) | 1 (25.0) | 139 (38.6) | 157 (43.5) | 271 (40.8) | 25 (44.6) | 107 (39.8) | 189 (41.8) | 257 (40.1) | 39 (48.8) |

SDH succinate dehydrogenase.
*Includes negative and low-positive cases.
Table 7 Clinicopathologic features according to the SDH expression phenotype in breast cancer

| Factors                  | Tumor phenotype | Stroma phenotype |
|--------------------------|-----------------|------------------|
|                          | SDHA (+)/ SDHB  | SDHA (+)/ SDHB   |
|                          | (+) n = 679 (%) | (+) n = 42 (%)   |
|                          | SDHA (+)/ SDHB  | SDHA (+)/ SDHB   |
|                          | (−) n = 1 (%)   | (−) n = 14 (%)   |
|                          | SDHA (+)/ SDHB  | SDHA (+)/ SDHB   |
|                          | (−) n = 18 (%)  | (−) n = 38 (%)   |
|                          | SDHA (+)/ SDHB  | SDHA (+)/ SDHB   |
|                          | (−) n = 23 (%)  | (−) n = 627 (%)  |
| **Histologic grade**     |                 | **P**            |
| I/II                     | 450 (66.3)      | 25 (59.5)        |
|                          | 1 (100.0)       | 7 (50.0)         |
|                          | 13 (72.2)       | 26 (68.4)        |
|                          | 20 (87.0)       | 426 (67.9)       |
| III                      | 229 (33.7)      | 17 (40.5)        |
|                          | 0 (0.0)         | 7 (50.0)         |
|                          | 5 (27.8)        | 12 (31.6)        |
|                          | 3 (13.0)        | 201 (32.1)       |
| **Tumor stage**          |                 | **P**            |
| T1                       | 329 (48.5)      | 20 (47.6)        |
|                          | 0 (0.0)         | 7 (50.0)         |
|                          | 6 (33.3)        | 24 (63.2)        |
|                          | 15 (65.2)       | 299 (47.7)       |
| T2/T3                    | 350 (51.5)      | 22 (52.4)        |
|                          | 1 (100.0)       | 7 (50.0)         |
|                          | 12 (66.7)       | 14 (36.8)        |
|                          | 8 (34.8)        | 328 (52.3)       |
| **Nodal stage**          |                 | **P**            |
| N0                       | 398 (58.6)      | 21 (50.0)        |
|                          | 1 (100.0)       | 4 (28.6)         |
|                          | 11 (61.1)       | 18 (47.4)        |
|                          | 15 (65.2)       | 253 (40.4)       |
| N1/N2/N3                 | 281 (41.4)      | 21 (50.0)        |
|                          | 0 (0.0)         | 4 (28.6)         |
|                          | 7 (38.9)        | 18 (47.4)        |
|                          | 8 (34.8)        | 253 (40.4)       |
| **ER**                   |                 | **P**            |
| Negative                 | 248 (36.5)      | 16 (38.1)        |
|                          | 1 (100.0)       | 10 (71.4)        |
|                          | 7 (38.9)        | 14 (36.8)        |
|                          | 5 (21.7)        | 221 (35.2)       |
| Positive                 | 431 (63.5)      | 26 (61.9)        |
|                          | 0 (0.0)         | 4 (28.6)         |
|                          | 11 (61.1)       | 24 (63.2)        |
|                          | 18 (78.3)       | 406 (64.8)       |
| **PR**                   |                 | **P**            |
| Negative                 | 324 (47.7)      | 21 (50.0)        |
|                          | 1 (100.0)       | 11 (78.6)        |
|                          | 11 (61.1)       | 17 (44.7)        |
|                          | 10 (43.5)       | 297 (47.4)       |
| Positive                 | 355 (52.3)      | 21 (50.0)        |
|                          | 0 (0.0)         | 3 (21.4)         |
|                          | 7 (38.9)        | 21 (55.3)        |
|                          | 13 (56.5)       | 330 (52.6)       |
| **HER-2**                |                 | **P**            |
| Negative                 | 539 (79.4)      | 26 (61.9)        |
|                          | 0 (0.0)         | 13 (92.9)        |
|                          | 14 (77.8)       | 21 (55.3)        |
|                          | 20 (87.0)       | 513 (81.8)       |
| Positive                 | 140 (20.6)      | 16 (38.1)        |
|                          | 1 (100.0)       | 1 (7.1)          |
|                          | 4 (22.2)        | 17 (44.7)        |
|                          | 3 (13.0)        | 114 (18.2)       |
| **Molecular type**       |                 | **P**            |
| Luminal A                | 281 (41.4)      | 14 (33.3)        |
|                          | 0 (0.0)         | 2 (14.3)         |
|                          | 6 (33.3)        | 11 (28.9)        |
|                          | 15 (65.2)       | 275 (43.9)       |
| Luminal B                | 160 (23.6)      | 13 (31.0)        |
|                          | 0 (0.0)         | 2 (14.3)         |
|                          | 5 (27.8)        | 13 (34.2)        |
|                          | 3 (13.0)        | 140 (22.3)       |
| HER-2                    | 63 (9.3)        | 9 (21.4)         |
|                          | 1 (100.0)       | 1 (7.1)          |
|                          | 3 (16.7)        | 9 (23.7)         |
|                          | 2 (8.7)         | 50 (8.0)         |
| TNBC                     | 175 (25.8)      | 6 (14.3)         |
|                          | 0 (0.0)         | 9 (64.3)         |
|                          | 4 (22.2)        | 5 (13.2)         |
|                          | 3 (13.0)        | 162 (25.8)       |
| **Ki-67 LI (%, mean ± SD)** | 17.5 ± 18.7     | 17.8 ± 15.3      |
|                          | 8.0 ± 0.0       | 24.3 ± 22.8      |
|                          | 16.8 ± 14.0     | 22.1 ± 19.0      |
|                          | 10.0 ± 10.2     | 16.8 ± 18.4      |
| **Tumor recurrence**     | 59 (8.7)        | 4 (9.5)          |
|                          | 0 (0.0)         | 1 (7.1)          |
|                          | 3 (16.7)        | 2 (5.3)          |
|                          | 1 (4.3)         | 56 (8.9)         |
| **Patient death**        | 56 (8.2)        | 3 (7.1)          |
|                          | 0 (0.0)         | 1 (7.1)          |
|                          | 3 (16.7)        | 3 (7.9)          |
|                          | 1 (4.3)         | 53 (8.5)         |

SDH succinate dehydrogenase.
### Table 8 Univariate analysis of disease-free survival and overall survival according to breast-tumor expression of hypoxia-related proteins

| Parameters          | Number of patients/recurrence/death | Disease-free survival | Overall survival |
|---------------------|-------------------------------------|-----------------------|------------------|
|                     |                                     | Mean survival (95% CI) months | Mean survival (95% CI) months | P-value | P-value |
| Nuclear HIF-1α      |                                     | 0.911                  | 0.943            |
| Negative            | 697/61/58                           | 126 (122 – 130)        | 129 (127 – 132)  |
| Positive            | 24/2/2                              | 120 (108 – 133)        | 131 (122 – 141)  |
| Cytoplasmic HIF-1α  | N/A                                 | N/A                    | N/A              |
| Negative            | 717/63                              | N/A                    | N/A              |
| Positive            | 4/0                                 | N/A                    | N/A              |
| Tumor SDHA          |                                     | 0.670                  | 0.085            |
| Negative/Low        | 360/35/26                           | 125 (121 – 129)        | 131 (128 – 135)  |
| High                | 361/28/34                           | 126 (120 – 132)        | 126 (121 – 130)  |
| Stromal SDHA        |                                     | 0.853                  | 0.901            |
| Negative            | 665/58/56                           | 126 (123 – 130)        | 130 (127 – 132)  |
| Positive            | 56/5/4                              | 115 (101 – 130)        | 121 (107 – 134)  |
| Tumor SDHB          |                                     | 0.124                  | 0.715            |
| Negative/Low        | 269/31/26                           | 123 (119 – 128)        | 129 (125 – 133)  |
| High                | 452/32/34                           | 126 (121 – 131)        | 129 (125 – 132)  |
| Stromal SDHB        |                                     | 0.821                  | 0.981            |
| Negative            | 641/57/54                           | 126 (122 – 130)        | 130 (127 – 132)  |
| Positive            | 80/6/6                              | 119 (110 – 128)        | 123 (114 – 131)  |

SDH succinate dehydrogenase. P-value by log-rank test.

### Table 9 Multivariate analysis for breast-cancer survival

| Parameters          | Disease-free survival | Overall survival |
|---------------------|-----------------------|------------------|
|                     | Hazard ratio 95% CI   | P-value | Hazard ratio 95% CI | P-value |
| T stage             |                       | 0.003     | 0.008            |
| T1 versus T2-3      | 2.535                 | 1.376 – 4.670 | 2.218 | 1.229 – 4.001 |
| N stage             | 0.002                 | 2.257     | 1.335 – 3.816 | 1.831 | 1.076 – 3.115 |
| Histologic grade    |                       | 0.045     | 1.685     | 1.013 – 2.804 | 0.726 | 0.748 – 2.176 |
| VII versus III      | 0.599                 | 1.685     | 1.013 – 2.804 | 0.726 | 0.748 – 2.176 |
| Nuclear HIF-1α      |                       | 0.096     | 0.682     | 0.163 – 2.846 | 0.599 | 0.142 – 2.528 |
| Tumor SDHA          | 0.290                 | 1.570     | 0.681 – 3.620 | 4.157 | 1.657 – 10.432 |
| Stromal SDHA        | 0.727                 | 1.254     | 0.352 – 4.468 | 0.807 | 0.218 – 2.978 |
| Tumor SDHB          | 0.096                 | 0.498     | 0.219 – 1.131 | 3.223 | 1.295 – 8.025 |
| Stromal SDHB        | 0.712                 | 1.254     | 0.352 – 4.468 | 0.807 | 0.218 – 2.978 |
| Negative versus Positive | 0.012   | 0.498     | 0.219 – 1.131 | 3.223 | 1.295 – 8.025 |

SDH succinate dehydrogenase.
negative (complete loss of expression); grade (2), low (expression in less than 50% of cells); and grade (3) high (expression in more than 50% of cells).

Several mechanisms have been proposed to explain the involvement of SDH mutation in tumorigenesis, among which a HIF-1α-pathway-dependent mechanism is the most famous. Loss-of-function mutation of SDH could result in an intracellular SDH accumulation, which in turn inhibits prolyl 4-hydroxylase (PHD), a negative regulator of HIF-1α (Cardaci & Cirilo 2012; Barletta & Hornick 2012). The impaired PHD activity stabilizes HIF-1α under normoxic condition, which upregulates HIF target gene involved in cell growth stimulation and angiogenesis, thus contributing to tumor progression. As loss-of-function mutations in SDH are predicted to stabilize HIF-1α and upregulate HIF-1 transcriptional activity, we examined the expression of HIF-1α along with SDHA/SDHB. However, we found no close relationship between HIF-1α and SDH expression in these breast cancers.

SDH-deficient GISTs and renal cell carcinomas display characteristic histologic features distinguishable from tumors without SDH mutation (Miettinen et al. 2011; Gill et al. 2011b). Similarly, the SDHA+/SDHB- and SDHA-/SDHB- breast cancers in this study were distinguished by lower histologic grade (Table 7), and in the SDHB-negative tumors, by lower Ki-67 LI (Table 5). The luminal A breast cancer subtype showed the highest frequency of low/negative SDHA expression (P = 0.032, Table 3). Based on these results, SDH mutation in breast cancer is associated with low histologic grade and a less aggressive molecular subtype.

Patients with SDHA- and SDHB-negative breast cancers were also younger than patients with intact SDH expression, although in the case of SDHB, this difference was not statistically significant. In earlier studies of SDH mutations in renal cell carcinomas (Baysal 2003), GISTs (Miettinen et al. 2011), paragangliomas, and pheochromocytomas (Gimenez-Roqueplo et al. 2003), tumors also occurred at younger ages.

Metabolism in many malignant tumors is characterized by the Warburg effect, which is a high level of anaerobic glucose metabolism by glycolysis despite presence of oxygen with relatively low mitochondrial oxidative phosphorylation (OXPHOS) (Warburg 1956). In this study, more than 50% of breast cancers expressed SDHA and SDHB, which are key components of aerobic glucose metabolism through the TCA cycle and mitochondrial electron transport. This finding of high mitochondrial activity in breast cancer agrees with an earlier report that breast cancer cells show high expression of mitochondrial metabolic enzymes such as cytochrome C oxidase, NADH, and SDHB (Whitaker-Menezes et al. 2011).

Expression of Glut-1 and CAIX (indicators of glycolysis) has also been observed in breast cancers, most notably in high-grade tumors such as TNBC or basal-like carcinoma (Choi et al. 2013; Pinheiro et al. 2011). While breast cancers overall may express high levels of activity in both OXPHOS and glycolysis, the predominant mode of energy metabolism may differ according to the tumor type (Moreno-Sanchez et al. 2007: Kallinowski et al. 1989; Liu et al. 2001).

Although most breast cancers in this study were negative for SDH in stromal elements, stromal SDHB expression differed significantly among the molecular subtypes. The HER-2 subtype showed the highest and TNBC showed the lowest frequency of stromal SDHB expression (Table 3). However, in a previous study, stromal cells in breast cancer did not express mitochondrial metabolic enzymes (cytochrome c oxidase, NADH, or SDHB) (Whitaker-Menezes et al. 2011). Further studies will be required to determine the differences in stromal SDHB expression among breast cancer molecular subtypes.

In conclusion, loss of SDHA or SDHB expression was detected in approximately 3% of the breast cancers in this study. Patients with SDH-deficient breast cancers were younger at diagnosis and presented tumors of relatively low-grade histology.

Consent
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Competing interest
The authors declare no conflict of interest.

Authors’ contributions
SK participated in the design of the study and performed the statistical analysis and drafted the manuscript. DHK carried out the immunoassays. WHJ participated in its design. JSK conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (2012R1A1A1002886).

Received: 10 June 2013 Accepted: 20 June 2013
Published: 3 July 2013

References
Anderson BO, Lawton TJ, Lehman CD, Moe RE (2004) Phyllodes tumor. In: Harris JR, Lippman ME, Morrow M, Osborne KC (eds) Disease of the Breast, 3rd edn. Lippincott & Wilkins, Philadelphia, pp 991–1006
Astuti D, Latif F, Dallo A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49–54. doi:10.1086/321262
Badve S, Dabbs DJ, Schmitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24:157–167. doi:10.1038/modpathol.2010.202
Barletta JA, Hornick JL (2012) Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications. Adv Anat Pathol 19:193–203. doi:10.1097/PAP.0b013e32835cb6c6

Baysal BE (2003) On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 14:435–459

Bumichon N, Briere JJ, Libre R, Vescovo L, Riviere J, Tissier F, Jouanno E, Jeunemaitre X, Benet P, Tzagaglof A, Rustin P, Bertherat J,avier F, Jimenez-Roqueplo AP (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19:3011–3020. doi:10.1093/hmg/ddq206

Cardaci S, Ciocci MR (2012) TCA cycle defects and cancer: when metabolism tunes redox state. Int J Cell Biol 2012:161837. doi:10.1155/2012/161837

Choi J, Jung WH, Koo JS (2013) Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology 80:41–52. doi:10.1159/000339513

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410

Gaj A, Stratakis CA, Carney JA, Ball ER, Kerpens-van Hoek E, Lodish MB, Levy L, Xekouki P, Van Nederveen FH, Den Bakker MA, O’Sullivan M, Dinjans WN, De Krijger RR (2011) SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 24:147–151. doi:10.1038/modpathol.2010.185

Gill AJ, Benn DE, Chou A, Clarkson A, Muljono A, Meyer-Rochow GY, Richardson AL, Sidhu SB, Robinson BG, Clifton-Bigham RJ (2010a) Immunohistochemistry for SDHB, SDHC, and SDHD in paragangioma-pheochromocytoma syndromes. Hum Pathol 41:805–814. doi:10.1016/j.hempath.2009.12.005

Gill AJ, Chou A, Vilain RE, Clifton-Bigham RJ (2011a) “Pediatric-type” gastrointestinal stromal tumors are SDHB negative ("type 2") GISTs. Am J Surg Pathol 35:1245–1247. doi:10.1097/PAS.0b013e31822f7bf3

Gill AJ, Pachter NS, Chou A, Young B, Clarkson A, Tucker KM, Winship IM, Earls P, Benn DE, Robinson BG, Fleming S, Clifton-Bigham RJ (2011b) Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 35:1578–1585. doi:10.1097/PAS.0b013e318227e794

Jimenez-Roqueplo AP, Favier J, Rustin P, Meatchi T, Badoual C, Bertherat J, Amar L, Alatkar D, Van Marck E, Ferrau F, Francois I, de Herder WW, Peeters MP, Van Linge A, Lenders JW, Jimenez-Roqueplo AP, De Krijger RR, Dinjans WN (2009) An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764–771. doi:10.1016/S1470-2045(09)70164-0

Warburg O (1956) On the origin of cancer cells. Science 123:309–314

Whitaker-Menezes D, Martinez-Outschoorn UE, Florenberg N, Birce RB, Witkiewicz AK, Howard A, Pavlides S, Tsirigos A, Estel A, Pestell RG, Broda P, Minetti C, Lisanti MP, Sotgia F (2011) Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 10:4047–4064. doi:10.4161/cc.10.23.18151

Wolff AC, Hammond ME, Herrmann JL, van der Vijver MJ, Hess WR, Dacic S, Maley FC, Austin H, Iversen P, A'Hern R, van de Vijver M, Baehir P, Sotgia F, Lindley S, Gennaro M, Oldenburg RA, De Bruyn EM, van Pagan EM, Meers S, White T, James D, Busch R, Martus C, Shurtleff S, Bolshoukian V, Castrigno A, Sotgia F, Wittkowsky AK, Witkiewicz AK, van der Vijver MJ, Moreno-Sanchez R, Buetow KH, Smith C, Neumann T, Hothg M, Fazio R, Ferrante A, Badoual C, Bertherat J, Lam A, Alatkar D, Van Marck E, Ferrau F, Francois I, de Herder WW, Peeters MP, Van Linge A, Lenders JW, Jimenez-Roqueplo AP, De Krijger RR, Dinjans WN (2009) An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764–771. doi:10.1016/S1470-2045(09)70164-0

Kim et al. SpringerPlus 2013, 2:299
http://www.springerplus.com/content/2/1/299

Cite this article as: Kim et al. Succinate dehydrogenase expression in breast cancer. SpringerPlus 2013;2:299.